| 摘要 |
The purpose of the present invention is to provide a vaccine composition which is safe and effective as a preventive medicine or a treatment medicine for infections and/or cancer, can effectively induce a systemic immune response and a mucosal immune response, and which is capable of being administered to the oral mucosa, ocular mucosa, ear mucosa, genital mucosa, pharyngeal mucosa, respiratory mucosa, bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, or rectal mucosa. The present invention is a mucosal vaccine composition administered to at least one type of mucous membrane of a person or animal, the mucous membrane being selected from a group comprising the oral mucosa, ocular mucosa, ear mucosa, genital mucosa, pharyngeal mucosa, respiratory mucosa, bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, and rectal mucosa. The mucosal vaccine composition is characterized by containing at least one type of antigen, and, as an immunostimulant agent, a lipopolysaccharide or a salt thereof derived from at least one type of a gram-negative bacterium selected from a group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter. Moreover, the mucosal vaccine composition is characterized in that the mass ratio of the abovementioned immunostimulant agent and antigen (the total mass of the immunostimulant agent/the total mass of the antigen) is between 0.002 and 500. |
